Creative medical technology holdings (nasdaq:celz) granted fda clearance to begin phase 1/2 clinical trial of allostem(tm) for addressing chronic lower back pain

Phoenix, az / accesswire / december 20, 2023 / creative medical technology holdings, inc. (nasdaq:celz), a biotechnology company has received clearance from the fda to conduct a phase 1/2 clinical trial using their innovative stemspine® treatment known as allostem™. this study aims to determine the safety, efficacy and tolerability of celz-201-ddt, a proprietary, ready-to-use cell line developed by the company.
CELZ Ratings Summary
CELZ Quant Ranking